Plenary Session 1
Monday, 13 October 2008 11:30 - 13:00, Auditorium
| Chair | Anthony E Woods | University of South Australia |
HSC Expansion for the Clinic
Dr David Haylock is best known for his pioneering work on blood stem cell mobilization and transplantation and long term interests in ex vivo manipulation of HSC. From 2000-2005, as Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre, David lead Australia’s first clinical trial with ex vivo expanded CD34+ cells in the setting of repetitive high dose chemotherapy for metastatic breast cancer. David is now at the Australian Stem Cell Centre and continues to participate in fundamental research on HSC and the HSC niche in collaboration with Associate Professor Susie Nilsson. |
Celebrate the Flat World
Prof Karen J.L. Burg, Hunter Endowed Chair and Professor of Bioengineering and Interim Vice Provost for Research & Innovation at Clemson University (Clemson University, Clemson, South Carolina, USA). A graduate of North Carolina State University (Raleigh, North Carolina, USA) and Clemson University (Clemson, South Carolina, USA), Dr. Burg completed a tissue engineering postdoctoral fellowship, at Carolinas Medical Center in Charlotte, North Carolina before joining the faculty at Clemson University. Dr. Burg is the Executive Editor of Biomaterials Forum and the Editor-in-Chief of the Journal of Histotechnology. Honors to Dr. Burg include a U.S. Presidential Early Career Award for Scientists and Engineers, the inaugural AO Foundation Research Prize, recognition as a Massachusetts Institute of Technology’s TR100 Young Innovator, an American Institute for Medical and Biological Engineering Fellow, an American Council on Education Fellow, and a United States Department of Defense Era of Hope Scholar. |